Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to $187180.0.

  • Cumberland Pharmaceuticals' Cash from Operations fell 6063.54% to $187180.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 56280.18%. This contributed to the annual value of -$612186.0 for FY2024, which is 11004.6% down from last year.
  • According to the latest figures from Q3 2025, Cumberland Pharmaceuticals' Cash from Operations is $187180.0, which was down 6063.54% from $843801.0 recorded in Q2 2025.
  • In the past 5 years, Cumberland Pharmaceuticals' Cash from Operations registered a high of $5.2 million during Q2 2023, and its lowest value of -$2.1 million during Q1 2024.
  • Its 5-year average for Cash from Operations is $1.3 million, with a median of $1.2 million in 2023.
  • Per our database at Business Quant, Cumberland Pharmaceuticals' Cash from Operations soared by 268347.66% in 2022 and then plummeted by 84234.41% in 2023.
  • Quarter analysis of 5 years shows Cumberland Pharmaceuticals' Cash from Operations stood at $2.0 million in 2021, then skyrocketed by 85.64% to $3.6 million in 2022, then crashed by 71.41% to $1.0 million in 2023, then surged by 83.12% to $1.9 million in 2024, then plummeted by 90.17% to $187180.0 in 2025.
  • Its Cash from Operations stands at $187180.0 for Q3 2025, versus $843801.0 for Q2 2025 and $3.9 million for Q1 2025.